Rutinib Cream contains Ruxolitinib, a Janus kinase (JAK) inhibitor that selectively blocks JAK1 and JAK2 enzymes, which are critical in the signaling of cytokines and growth factors involved in hematopoiesis and immune responses. By inhibiting JAK-STAT signaling, Ruxolitinib reduces inflammation, abnormal immune activity, and the progression of inflammatory skin conditions.

Rutinib is a topical formulation intended for the treatment of atopic dermatitis and nonsegmental vitiligo, providing targeted local effects while minimizing systemic exposure. The cream has been shown to improve skin lesions, reduce itching, and support repigmentation in affected areas.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Rutinib Cream is indicated for:

• Atopic Dermatitis:

  • Reduction of inflammation, redness, and itching associated with mild to moderate disease

  • Management of affected skin areas up to 20% of body surface area

• Nonsegmental Vitiligo:

  • Supports repigmentation of depigmented areas

  • Treatment of affected areas up to 10% of body surface area

Note: Safety and efficacy in pediatric patients under 12 years have not been established.

Therapeutic Class

• Pyrrolopyrimidines (JAK inhibitor)

Pharmacology

• Ruxolitinib inhibits JAK1 and JAK2, preventing activation of STAT transcription factors and modulating gene expression.

• Plasma protein binding: ~97%

• Terminal half-life: ~116 hours after topical application

• Metabolized primarily via CYP3A4 and to a lesser extent CYP2C9

• Excretion: ~74% urine, 22% feces; <1% unchanged drug

Dosage & Administration

• Atopic Dermatitis: Apply a thin layer twice daily to affected areas, up to 20% body surface area. Maximum: 60 g/week or 100 g/2 weeks. Discontinue when symptoms resolve; reassess if no improvement in 8 weeks.

• Nonsegmental Vitiligo: Apply a thin layer twice daily to affected areas, up to 10% body surface area. Treatment may continue for over 24 weeks if clinically meaningful repigmentation occurs; reassess if ineffective by 24 weeks.

Topical use only – do not apply intraocularly, orally, or intravaginally.

Drug Interactions

• Substrate of CYP3A4: Strong inhibitors (e.g., ketoconazole, clarithromycin) may increase systemic exposure and risk of adverse reactions

• Strong inducers (e.g., rifampicin, carbamazepine) may decrease effectiveness

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Known hypersensitivity to Ruxolitinib or any excipients in the cream

Side Effects

Atopic Dermatitis:

• Nasopharyngitis, diarrhea, bronchitis, ear infection, increased eosinophils, urticaria, folliculitis, tonsillitis, rhinorrhea

Nonsegmental Vitiligo:

• Application site acne or pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia

Precautions & Warnings

• Serious infections: Avoid use in active infections; interrupt therapy if infection occurs

• Cardiovascular risk: Monitor in patients with risk factors; avoid in patients with history of myocardial infarction or stroke

• Skin cancer: Periodic examination recommended; limit UV exposure

• Hematologic effects: Thrombocytopenia, anemia, neutropenia; monitor CBC as clinically indicated

• Thromboembolism: Discontinue if thrombosis occurs

Pregnancy & Lactation

• Breastfeeding should be avoided during treatment and for ~4 weeks after last dose due to risk of serious adverse effects

Storage Conditions

• Store below 30°C in a dry place, protected from sunlight

• Keep out of reach of children.